o2h Ventures backs visionary teams in UK biotech, leveraging AI and data-driven approaches to accelerate drug discovery and development. The fund focuses on high-potential exits in oncology, neuroscience, and other critical disease areas, while providing SEIS/EIS tax benefits to UK investors. The team operates from Mill SciTech Park, offering incubation and grassroots scientific collaboration.
Bevorzugte Reifephase für die erste Finanzierung.
Early-stage biotech and life sciences companies, with a focus on AI-driven drug discovery, therapeutics, and digital health solutions
Thematische Schwerpunkte und Zielmarktsegmente von Interesse.
Standard-Finanzierungsbetrag pro Runde.
Verifiziertes E-Mail-Muster
Analysen-Scorecard der Investitionsthese
Unser KI-Analyzer hat Portfolio-Unternehmen gescannt und verifizierte Übereinstimmungen berechnet...
